Released Aug 4, 2023, before the open
10-Q filed Aug 4, 2023, 35 days after period end · 0001628280-23-027402
Q2 2023 · 10-Q
Revenue$5.60M$5.60M +24.7% vs Q2 2022+5.5% vs Q1 2023
Net Income-$29.49M-$29.49M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.70-$0.70 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$32,050,000N/M
Operating Cash Flowderived-$32,175,000N/M
Free Cash Flowderived-$32,644,000N/M
Margins · derived
Operating margin-572.4%+77.6 pt vs Q2 2022
Net margin-526.6%+81.7 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $5.60M | $4.49M | $279.00K | $0.00 |
| Net Income | -$29.49M | -$27.31M | -$23.11M | -$15.72M |
| EPS Diluted | -$0.70 | -$0.66 | -$0.63 | -$2.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR